Amiodarone

Introduction Overview

Generic Name

Amiodarone

Brand Name

Pacerone

Dosage Form

Oral tablets and Intravenous infusion

Drug Class

Group III antiarrhythmics

Pharmacokinetics

Absorption

Amiodarone is variably absorbed from the gastrointestinal tract when administered orally, with bioavailability ranging from approximately 30% to 80%. The variability is due to extensive first-pass metabolism and individual patient differences. Peak plasma concentrations are typically achieved within 3 to 7 hours post-dose. The drug’s absorption can be influenced by food intake, but it is generally recommended to take it consistently with or without food to maintain stable plasma levels.

Distribution

Amiodarone has an extensive volume of distribution reflecting its accumulation in various tissues including adipose tissue, liver, lungs, and heart. It’s highly lipophilic and concentrates significantly in organs rich in lipids. It binds extensively to tissues, contributing to the drug's long half-life and prolonged duration of action. Plasma protein binding is high, approximately 96%, mainly to albumin and alpha-1 acid glycoprotein. Due to its tissue accumulation, the drug pool continues to release slowly back into circulation even after cessation of therapy.

Metabolism

Amiodarone undergoes hepatic metabolism primarily via cytochrome P450 enzymes, predominantly CYP3A4 and CYP2C8, to its major active metabolite desethylamiodarone, which also participates in antiarrhythmic activity. The metabolism involves oxidative dealkylation and other processes. The metabolic clearance is slow and variable among individuals, influenced by genetic and environmental factors, as well as concurrent medications that inhibit or induce CYP enzymes.

Elimination

The elimination half-life of amiodarone is extremely prolonged, averaging 40 to 55 days, but can range from 20 up to 100 days, depending on treatment duration and individual factors. Excretion occurs mainly via biliary routes into the feces; less than 1% of the drug is eliminated unchanged in urine. This extensive elimination half-life accounts for the prolonged pharmacodynamic effects and necessitates careful dosing and monitoring during therapy initiation and discontinuation.

Dosage Forms

Adults

For arrhythmias, amiodarone is administered orally as tablets with loading doses ranging from 800 mg to 1600 mg daily for 1 to 3 weeks to attain therapeutic levels. The dose is then reduced to a maintenance oral dose of approximately 400 mg daily, with some patients requiring up to 600 mg daily based on efficacy and tolerance. Intravenous formulations are used in hospital settings for acute arrhythmia management with initial 24 hour dosing regimens totaling approximately 1000 mg via loading and maintenance infusions, continuing with maintenance doses as needed for up to 3 weeks.

Adolescents

Use in adolescents is generally similar to adult dosing guidelines but must be individualized based on clinical response, weight, and tolerability. Because of limited pediatric data, treatment initiation under specialist supervision with close monitoring is recommended.

Special Populations

In patients with hepatic impairment, caution is advised as metabolism may be impaired leading to accumulation and enhanced toxicity risk. No specific dose adjustment guidelines exist, but clinical monitoring for adverse effects is critical. In renal impairment, no dose adjustment is recommended due to minimal renal excretion. In elderly patients, due to altered pharmacokinetics and increased susceptibility to side effects, starting doses should be conservative with careful monitoring. Use during pregnancy is contraindicated due to potential fetal harm; breast-feeding is not recommended during treatment and for several months after cessation due to drug persistence in the body. Dosage adjustments are primarily guided by therapeutic response and toxicity monitoring rather than strict numerical protocols.

Mechanism Of Action

Amiodarone primarily exerts its antiarrhythmic effect by prolonging the myocardial cell-action potential duration and refractory period. It achieves this by blocking potassium channels responsible for repolarization in cardiac cells (Class III antiarrhythmic effect), thereby reducing abnormal automaticity and suppressing reentrant circuits that cause arrhythmias. This lengthening of the action potential suppresses ectopic pacemaker activity and delays conduction through cardiac tissues.

Additionally, amiodarone exhibits multichannel effects: it blocks sodium channels (Class I effect), calcium channels (Class IV effect), and noncompetitively blocks beta-adrenergic receptors (Class II effect). These combined actions contribute to decreased conduction velocity, slowed AV node conduction, and reduced heart rate. The comprehensive channel blockade stabilizes cardiac electrical activity in supraventricular and ventricular arrhythmias.

At the cellular level, amiodarone disrupts ion fluxes across myocardial cell membranes, reducing excitability and conduction heterogeneity. Its lipophilic nature allows accumulation in cellular membranes, affecting the lipid microenvironment and modulating receptor and channel functions. Clinically, these mechanisms translate into effective suppression of ventricular fibrillation, ventricular tachycardia, and other life-threatening arrhythmias.

Comparatively, unlike other Class III antiarrhythmics such as sotalol or dofetilide, amiodarone's combined multiple channel blockade provides a broader spectrum of antiarrhythmic activity but also contributes to its complex side effect profile. Its metabolite desethylamiodarone retains potent antiarrhythmic properties, prolonging the drug’s efficacy after discontinuation. Numerous clinical trials have demonstrated amiodarone’s efficacy in reducing mortality in patients with refractory ventricular arrhythmias, establishing it as a critical therapeutic agent in cardiac electrophysiology.

Pharmacological Actions

Prolongs myocardial action potential duration by blocking potassium channels (Class III antiarrhythmic effect)
Blocks sodium channels, reducing conduction velocity (Class I effect)
Noncompetitive inhibition of beta-adrenergic receptors, decreasing sympathetic stimulation (Class II effect)
Blocks L-type calcium channels, slowing AV node conduction (Class IV effect)
Suppresses abnormal automaticity and arrhythmogenic foci
Extends refractory periods in atrial and ventricular myocardium
Reduces incidence of ventricular tachycardia and fibrillation
Decreases conduction through accessory pathways in the heart
Exhibits vasodilatory effects on coronary vessels
Accumulates in myocardial and other tissues, contributing to sustained action

Therapeutic Clinical Uses

Management of life-threatening recurrent ventricular fibrillation (VF)
Treatment of hemodynamically unstable ventricular tachycardia (VT) refractory to other therapies
Prevention of recurrent ventricular arrhythmias in patients with structural heart disease
Control of supraventricular tachyarrhythmias when other agents are ineffective or contraindicated
Use in patients with implanted pacemakers or defibrillators who require arrhythmia suppression
Acute arrhythmia management via intravenous administration in hospital settings
Adjunct therapy for arrhythmias resistant to conventional antiarrhythmic drugs
Off-label use in certain atrial arrhythmias under specialist guidance

Side Or Adverse Effects

Pulmonary toxicity including pneumonitis and pulmonary fibrosis
Thyroid dysfunction: hypothyroidism or hyperthyroidism due to iodine content
Hepatotoxicity presenting as elevated liver enzymes or hepatitis
Cardiac adverse effects: bradycardia, heart block, arrhythmias including torsades de pointes
Visual disturbances including blurred vision, corneal microdeposits, and optic neuropathy
Neurological effects such as peripheral neuropathy, tremor, ataxia, and dizziness
Gastrointestinal effects including nausea, vomiting, and constipation
Photosensitivity leading to easy sunburn and skin discoloration
Skin reactions such as blue-grey pigmentation with long-term use
Fatigue and malaise
Hypotension especially during intravenous administration
Rare hypersensitivity reactions including angioedema and anaphylaxis
Elevated serum creatinine and potential renal dysfunction
Potential interaction with pulmonary fibrosis with concurrent oxygen therapy

Precautions

Regular monitoring of pulmonary function and chest imaging due to risk of lung toxicity
Frequent thyroid function tests to detect hypo- or hyperthyroidism early
Periodic liver function tests to monitor for hepatotoxicity
Regular ECG and cardiac monitoring for bradyarrhythmias or conduction defects
Avoid use in patients with severe sinus node dysfunction or AV block unless pacemaker is present
Careful electrolyte monitoring especially potassium and magnesium to reduce arrhythmia risk
Avoid grapefruit consumption due to drug interaction risk
Sun protection advised to prevent photosensitivity reactions
Caution in patients with pre-existing liver, lung, or thyroid disease
Close supervision during loading and dose adjustments to balance efficacy and toxicity
Avoid concurrent use with other proarrhythmic drugs unless well monitored
Counsel patients on signs and symptoms of pulmonary, hepatic, and thyroid dysfunction
Discontinue promptly if severe toxicity develops
Adjust doses cautiously in elderly patients due to increased sensitivity

Warnings

Potential for life-threatening arrhythmias despite therapeutic use
Risk of severe pulmonary toxicity which can be fatal if not recognized early
Possibility of liver failure and hepatic injury requiring drug discontinuation
Prolonged QT interval increasing risk of torsades de pointes
Can cause optic neuropathy leading to visual impairment or blindness
Pregnancy category D: may cause fetal harm and affect neonatal thyroid function and development
Breastfeeding contraindicated due to drug excretion in milk and long half-life
Risk of sensitization to iodine-containing compounds in allergic individuals
Drug accumulates in body; adverse effects may persist months after therapy cessation
Must be used only for life-threatening arrhythmias due to serious side effect profile
May potentiate effects of warfarin and increase bleeding risk
Intravenous administration may cause hypotension and bradycardia requiring monitoring
Abrupt withdrawal may precipitate arrhythmia recurrence
Use caution in patients with implanted defibrillators as amiodarone may alter device function

Contraindications

Hypersensitivity to amiodarone or any component including iodine
Second- or third-degree AV block in absence of a pacemaker
Bradycardia causing syncope or sinus node dysfunction without pacemaker support
Severe sinus node dysfunction without pacemaker
Cardiogenic shock or severe hypotension
Severe hepatic impairment
Known iodine sensitivity or allergy
Pregnancy unless benefits outweigh risks and no alternatives exist
Breastfeeding due to long elimination half-life and toxicity risk
Use with caution when alternate antiarrhythmics are effective and safer

Drug Interactions

Increased risk of QT prolongation when combined with other QT-prolonging drugs (e.g., sotalol, quinidine)
Potentiation of warfarin anticoagulant effect, requiring INR monitoring
Increased plasma concentrations of digoxin leading to toxicity
Inhibition of cytochrome P450 enzymes (CYP3A4 and CYP2C8) affecting metabolism of many drugs such as statins
Interaction with beta-blockers and calcium channel blockers may cause additive bradycardia or AV block
Grapefruit juice inhibits amiodarone metabolism leading to elevated levels and toxicity
Concurrent use with drugs inducing CYP enzymes (e.g., rifampin) reduces amiodarone efficacy
Increased risk of myopathy when used with HMG-CoA reductase inhibitors
Interactions with thyroid medications complicating thyroid status management
Potential additive hypotension with anti-hypertensives
St. John's wort may reduce amiodarone plasma levels and effectiveness
Concurrent use with phenytoin and carbamazepine affects amiodarone metabolism and toxicity risk
Co-administration with cyclosporine increases risk of nephrotoxicity
Amiodarone may affect serum levels and toxicity of various antiarrhythmics and anticonvulsants

Preparations Of The Drug

Oral tablets commonly available in 100 mg and 200 mg strengths
Intravenous infusion formulations supplied in concentrations suitable for continuous administration
Commercial brand names include Pacerone, Cordarone, Nexterone
Formulations designed for hospital-based acute arrhythmia management
Usually packaged with patient information leaflets detailing administration and monitoring guidelines
Available as immediate-release forms for oral administration
Reconstitutable intravenous formulations for controlled infusion under monitoring
Different formulations standardized for stability and storage conditions